Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Buyout
This article was originally published in The Pink Sheet Daily
Executive Summary
A bidding war for a start-up developing a promising late-stage melanoma drug drives the deal value sky high.
You may also be interested in...
Yervoy Approval Has Shifted Development Landscape For Melanoma
With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.
Yervoy Approval Has Shifted Development Landscape For Melanoma
With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.
Hopes Rise For Approval Of Melanoma Drug Ipilimumab, With Positive Front-line Results
As Bristol-Myers' ipilimumab nears its March 26 PDUFA date for second-line melanoma, drug demonstrates good results in front-line study. Will the data sway regulators?